Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology
HONG KONG, June 11, 2026 (GLOBE NEWSWIRE) -- Copley Acquisition Corp (NYSE: COPL) (“Copley”), a special purpose acquisition company and Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), a leader in pathway-level protein analytics to guide precision oncology, announced today that they have entered into a definitive business combination agreement (“BCA”).
HONG KONG, June 11, 2026 (GLOBE NEWSWIRE) -- Copley Acquisition Corp (NYSE: COPL) (“Copley”), a special purpose acquisition company and Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), a leader in pathway-level protein analytics to guide precision oncology, announced today that they have entered into a definitive business combination agreement (“BCA”).
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.